These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 23953216)

  • 21. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
    Wilens TE; Verlinden MH; Adler LA; Wozniak PJ; West SA
    Biol Psychiatry; 2006 Jun; 59(11):1065-70. PubMed ID: 16499880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of nicotine on social cognition, social competence and self-reported stress in schizophrenia patients and healthy controls.
    Drusch K; Lowe A; Fisahn K; Brinkmeyer J; Musso F; Mobascher A; Warbrick T; Shah J; Ohmann C; Winterer G; Wölwer W
    Eur Arch Psychiatry Clin Neurosci; 2013 Sep; 263(6):519-27. PubMed ID: 23081705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-administration of intravenous nicotine in male and female cigarette smokers.
    Sofuoglu M; Yoo S; Hill KP; Mooney M
    Neuropsychopharmacology; 2008 Mar; 33(4):715-20. PubMed ID: 17534380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics.
    Cole DM; Beckmann CF; Long CJ; Matthews PM; Durcan MJ; Beaver JD
    Neuroimage; 2010 Aug; 52(2):590-9. PubMed ID: 20441798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal.
    Atzori G; Lemmonds CA; Kotler ML; Durcan MJ; Boyle J
    J Clin Psychopharmacol; 2008 Dec; 28(6):667-74. PubMed ID: 19011436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A review of the effects of nicotine on schizophrenia].
    Bidzan L
    Psychiatr Pol; 2007; 41(5):737-44. PubMed ID: 18421928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial.
    Liu F; Guo X; Wu R; Ou J; Zheng Y; Zhang B; Xie L; Zhang L; Yang L; Yang S; Yang J; Ruan Y; Zeng Y; Xu X; Zhao J
    Schizophr Res; 2014 Mar; 153(1-3):169-76. PubMed ID: 24503176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia.
    Kontis D; Theochari E; Kleisas S; Kalogerakou S; Andreopoulou A; Psaras R; Makris Y; Karouzos C; Tsaltas E
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1333-41. PubMed ID: 20691745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of nicotine on cognition are dependent on baseline performance.
    Niemegeers P; Dumont GJ; Quisenaerts C; Morrens M; Boonzaier J; Fransen E; de Bruijn ER; Hulstijn W; Sabbe BG
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1015-23. PubMed ID: 24766971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia.
    George MS; Molnar CE; Grenesko EL; Anderson B; Mu Q; Johnson K; Nahas Z; Knable M; Fernandes P; Juncos J; Huang X; Nichols DE; Mailman RB
    Schizophr Res; 2007 Jul; 93(1-3):42-50. PubMed ID: 17467956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
    Yi Z; Fan X; Wang J; Liu D; Freudenreich O; Goff D; Henderson DC
    Psychiatry Res; 2012 Dec; 200(2-3):79-82. PubMed ID: 22727707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.
    Harvey PD; Ogasa M; Cucchiaro J; Loebel A; Keefe RS
    Schizophr Res; 2011 Apr; 127(1-3):188-94. PubMed ID: 21277745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia.
    Smith RC; Singh A; Infante M; Khandat A; Kloos A
    Neuropsychopharmacology; 2002 Sep; 27(3):479-97. PubMed ID: 12225705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A transdermal nicotine patch is not effective for postoperative pain management in smokers: a pilot dose-ranging study.
    Olson LC; Hong D; Conell-Price JS; Cheng S; Flood P
    Anesth Analg; 2009 Dec; 109(6):1987-91. PubMed ID: 19923530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.
    Potter AS; Newhouse PA
    Pharmacol Biochem Behav; 2008 Feb; 88(4):407-17. PubMed ID: 18022679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous nicotine and caffeine: subjective and physiological effects in cocaine abusers.
    Garrett BE; Griffiths RR
    J Pharmacol Exp Ther; 2001 Feb; 296(2):486-94. PubMed ID: 11160635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α7 Nicotinic receptor agonists as cognitive treatments: is less (or less often) more?
    Buchanan RW; Schwarcz R
    Biol Psychiatry; 2011 Jan; 69(1):5-6. PubMed ID: 21145443
    [No Abstract]   [Full Text] [Related]  

  • 40. Dose-related enhancement of mood and cognition in smokers administered nicotine nasal spray.
    Myers CS; Taylor RC; Moolchan ET; Heishman SJ
    Neuropsychopharmacology; 2008 Feb; 33(3):588-98. PubMed ID: 17443125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.